<DOC>
	<DOC>NCT00224042</DOC>
	<brief_summary>This study compares the effect of Ferrlecit® (a form of intravenous iron) to ferrous sulfate (a form of oral iron) in treating anemia and iron deficiency in chronic kidney disease patients who are receiving erythropoietic agents, such as Procrit® and Aranesp®.</brief_summary>
	<brief_title>Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients Receiving Erythropoietic Agents</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Anemia, Iron-Deficiency</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure, Chronic</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric gluconate</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Moderate to severe anemia Iron deficiency Moderate to severe chronic kidney disease Receiving therapy with erythropoietic agent Receiving dialysis Known sensitivity to Ferrlecit® or any of its components Clinically unstable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Iron deficiency</keyword>
	<keyword>Anemia</keyword>
	<keyword>Chronic kidney disease</keyword>
	<keyword>Erythropoietic agents</keyword>
	<keyword>Sodium Ferric Gluconate</keyword>
	<keyword>Anemia, Iron-Deficiency/drug therapy/etiology</keyword>
	<keyword>Kidney Failure, Chronic/blood/complications/therapy</keyword>
	<keyword>Erythropoietin, Recombinant/adverse effects/therapeutic use</keyword>
</DOC>